Bardy Diagnostics Reveals $375M Total Funding; $36M Series B Recorded in April 2019

Bardy Diagnostics, headquartered in New Providence, NJ, has disclosed $375M in total funding, with its latest recorded round a $36M Series B in April 2019. The company’s leadership links to Baxter International via Andrew Hider, and investors include River Cities Capital Funds, HealthQuest Capital, Aperture Venture Partners, and others.

No comments yet.